Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R

Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R

•The FEOS score and Upham criteria are useful tools that help the clinician in clinical practice.•Both tools can help to make a decision in maintain or discontinue the biologic treatment.•FEOS=75 could be the suitable cut-off point to identify super-responders.•We may wait until second year to evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respiratory medicine 2023-05, Vol.211, p.107216-107216, Article 107216
Hauptverfasser: Laorden, Daniel, Zamarrón, Ester, Romero, David, Domínguez-Ortega, Javier, Villamañán, Elena, Losantos, Itsaso, Gayá, Francisco, Quirce, Santiago, Álvarez-Sala, Rodolfo
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Asthmatic Agents - therapeutic use
Anti-IL5
Anti-IL5R
Asthma
Asthma - drug therapy
Asthma remission
Benralizumab
Biologic treatment
FEOS score
Humans
Mepolizumab
Reslizumab
Super-responder
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•The FEOS score and Upham criteria are useful tools that help the clinician in clinical practice.•Both tools can help to make a decision in maintain or discontinue the biologic treatment.•FEOS=75 could be the suitable cut-off point to identify super-responders.•We may wait until second year to evaluate superresponse after an anti-IL5/R treatment.
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2023.107216